Skip to main content

Linking proteomic alterations in schizophrenia hippocampus to NMDAr hypofunction in human neurons and oligodendrocytes


Glutamatergic neurotransmission dysfunction and the early involvement of the hippocampus have been proposed to be important aspects of the pathophysiology of schizophrenia. Here, we performed proteomic analysis of hippocampus postmortem samples from schizophrenia patients as well as neural cells—neurons and oligodendrocytes—treated with MK-801, an NMDA receptor antagonist. There were similarities in processes such as oxidative stress and apoptotic process when comparing hippocampus samples with MK-801-treated neurons, and in proteins synthesis when comparing hippocampus samples with MK-801-treated oligodendrocytes. This reveals that studying the effects of glutamatergic dysfunction in different neural cells can contribute to a better understanding of what it is observed in schizophrenia patients’ postmortem brains.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 3


  1. 1.

    James SL, Abate D, Abate KH et al (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392:1789–1858.

    Article  Google Scholar 

  2. 2.

    Javitt DC (2007) Glutamate and schizophrenia: phencyclidine, N-methyl-d-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol 78:69–108.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Paz RD, Tardito S, Atzori M, Tseng KY (2008) Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur Neuropsychopharmacol 18:773–786.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Adler CM, Malhotra AK, Elman I et al (1999) Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 156:1646–1649.

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Krystal JH, Karper LP, Seibyl JP et al (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199–214.

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Hu W, MacDonald ML, Elswick DE, Sweet RA (2015) The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies. Ann NY Acad Sci 1338:38–57.

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Poels EMP, Kegeles LS, Kantrowitz JT et al (2014) Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. Schizophr Res 152:325–332.

    Article  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Harrison PJ, Law AJ, Eastwood SL (2003) Glutamate receptors and transporters in the hippocampus in schizophrenia. Ann NY Acad Sci 1003:94–101.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Tamminga CA, Stan AD, Wagner AD (2010) The hippocampal formation in schizophrenia. Am J Psychiatry 167:1178–1193.

    Article  PubMed  Google Scholar 

  10. 10.

    Weinberger DR (1999) Cell biology of the hippocampal formation in schizophrenia. Biol Psychiatry 45:395–402.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Weinberger DR, Berman KF, Suddath R, Torrey EF (1992) Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins. Am J Psychiatry 149:890–897.

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301–1308.

    CAS  Article  PubMed  Google Scholar 

  13. 13.

    Karasawa J-i, Hashimoto K, Chaki S (2008) d-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav Brain Res 186:78–83.

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Stone J (2009) Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia. Curr Pharm Des 15:2594–2602.

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Rung JP, Carlsson A, Markinhuhta KR, Carlsson ML (2005) (+)-MK-801 induced social withdrawal in rats: a model for negative symptoms of schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 29:827–832.

    CAS  Article  Google Scholar 

  16. 16.

    Cassoli JS, Iwata K, Steiner J et al (2016) Effect of MK-801 and clozapine on the proteome of cultured human oligodendrocytes. Front Cell Neurosci 10:52.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  17. 17.

    Guest PC, Iwata K, Kato TA et al (2015) MK-801 treatment affects glycolysis in oligodendrocytes more than in astrocytes and neuronal cells: insights for schizophrenia. Front Cell Neurosci 09:1–10.

    CAS  Article  Google Scholar 

  18. 18.

    Martins-de-Souza D, Lebar M, Turck CW (2011) Proteome analyses of cultured astrocytes treated with MK-801 and clozapine: similarities with schizophrenia. Eur Arch Psychiatry Clin Neurosci 261:217–228.

    Article  PubMed  Google Scholar 

  19. 19.

    Cao N, Yao ZX (2013) Oligodendrocyte N-methyl-D-aspartate receptor signaling: insights into its functions. Mol Neurobiol 47:845–856.

    CAS  Article  PubMed  Google Scholar 

  20. 20.

    Li C, Xiao L, Liu X et al (2013) A functional role of nmda receptor in regulating the differentiation of oligodendrocyte precursor cells and remyelination. Glia 61:732–749.

    Article  PubMed  Google Scholar 

  21. 21.

    Cassoli JS, Guest PC, Malchow B et al (2015) Disturbed macro-connectivity in schizophrenia linked to oligodendrocyte dysfunction: From structural findings to molecules. npj Schizophr.

    Article  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Takahashi N, Sakurai T, Davis KL, Buxbaum JD (2011) Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia. Prog Neurobiol 93:13–24.

    CAS  Article  PubMed  Google Scholar 

  23. 23.

    Falkai P, Malchow B, Wetzestein K et al (2016) Decreased oligodendrocyte and neuron number in anterior hippocampal areas and the entire hippocampus in schizophrenia: a stereological postmortem study. Schizophr Bull 42:S4–S12.

    Article  PubMed  PubMed Central  Google Scholar 

  24. 24.

    Falkai P, Steiner J, Malchow B et al (2016) Oligodendrocyte and interneuron density in hippocampal subfields in schizophrenia and association of oligodendrocyte number with cognitive deficits. Front Cell Neurosci 10:1–13.

    CAS  Article  Google Scholar 

  25. 25.

    Schmitt A, Steyskal C, Bernstein HG et al (2009) Stereologic investigation of the posterior part of the hippocampus in schizophrenia. Acta Neuropathol 117:395–407.

    Article  PubMed  Google Scholar 

  26. 26.

    Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239–259.

    CAS  Article  PubMed  Google Scholar 

  27. 27.

    Braak H, Alafuzoff I, Arzberger T et al (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112:389–404.

    Article  PubMed  PubMed Central  Google Scholar 

  28. 28.

    Jahn T, Mussgay L (1989) Die statistische Kontrolle möglicher Medikamenteneinflüsse in experimentalpsychologischen Schizophreniestudien: Ein Vorschlag zur Berechnung von Chlorpromazinäquivalenten. Zeitschrift für Klin Psychol 18:257–267

    Google Scholar 

  29. 29.

    Fatemi S, Meltzer H (1998) Treatment of schizophrenia. In: The American psychiatric text book of psychopharmacology. pp 127–135

  30. 30.

    Breuer K, Foroushani AK, Laird MR et al (2013) InnateDB: systems biology of innate immunity and beyond—recent updates and continuing curation. Nucleic Acids Res 41:1228–1233.

    CAS  Article  Google Scholar 

  31. 31.

    Boyer P, Phillips JL, Rousseau FL, Ilivitsky S (2007) Hippocampal abnormalities and memory deficits: new evidence of a strong pathophysiological link in schizophrenia. Brain Res Rev 54:92–112.

    CAS  Article  PubMed  Google Scholar 

  32. 32.

    Ellgaard L, Helenius A (2003) Quality control in the endoplasmic reticulum. Nat Rev Mol Cell Biol 4:181–191.

    CAS  Article  PubMed  Google Scholar 

  33. 33.

    Harding HP, Zhang Y, Ron D (1999) Protein translation and folding are coupled by an endoplasmic- reticulum-resident kinase. Nature 397:271–274.

    CAS  Article  PubMed  Google Scholar 

  34. 34.

    Welihinda AA, Tirasophon W, Kaufman RJ (1999) The cellular response to protein misfolding in the endoplasmic reticulum. Gene Expr 7:293–300

    CAS  PubMed  Google Scholar 

  35. 35.

    Vembar SS, Brodsky JL (2008) One step at a time: endoplasmic reticulum-associated degradation. Nat Rev Mol Cell Biol 9:944–957.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  36. 36.

    Kim P, Scott MR, Meador-Woodruff JH (2018) Abnormal expression of ER quality control and ER associated degradation proteins in the dorsolateral prefrontal cortex in schizophrenia. Schizophr Res 197:484–491.

    Article  PubMed  PubMed Central  Google Scholar 

  37. 37.

    Heckers S (2001) Neuroimaging studies of the hippocampus in schizophrenia. Hippocampus 11:520–528.

    CAS  Article  PubMed  Google Scholar 

  38. 38.

    Perez JM, Berto S, Gleason K et al (2020) Hippocampal subfield transcriptome analysis in schizophrenia psychosis. Mol Psychiatry.

    Article  PubMed  Google Scholar 

  39. 39.

    Schobel SA, Chaudhury NH, Khan UA et al (2013) Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron 78:81–93.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  40. 40.

    Lieberman JA, Girgis RR, Brucato G et al (2018) Hippocampal dysfunction in the pathophysiology of schizophrenia: a selective review and hypothesis for early detection and intervention. Mol Psychiatry 23:1764–1772.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  41. 41.

    Li W, Ghose S, Gleason K et al (2015) Synaptic proteins in the hippocampus indicative of increased neuronal activity in CA3 in schizophrenia. Am J Psychiatry 172:373–382.

    Article  PubMed  PubMed Central  Google Scholar 

  42. 42.

    Segev A, Yanagi M, Scott D et al (2018) Reduced GluN1 in mouse dentate gyrus is associated with CA3 hyperactivity and psychosis-like behaviors. Mol Psychiatry 176:139–148.

    Article  Google Scholar 

  43. 43.

    Hardingham GE, Do KQ (2016) Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis. Nat Rev Neurosci 17:125–134.

    CAS  Article  PubMed  Google Scholar 

  44. 44.

    Che Y, Wang JF, Shao L, Young LT (2010) Oxidative damage to RNA but not DNA in the hippocampus of patients with major mental illness. J Psychiatry Neurosci 35:296–302.

    Article  PubMed  PubMed Central  Google Scholar 

  45. 45.

    Nishioka N, Arnold SE (2004) Evidence for oxidative DNA damage in the hippocampus of elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry 12:167–175.

    Article  PubMed  Google Scholar 

  46. 46.

    Wilson C, González-Billault C (2015) Regulation of cytoskeletal dynamics by redox signaling and oxidative stress: implications for neuronal development and trafficking. Front Cell Neurosci 9:1–10.

    CAS  Article  Google Scholar 

  47. 47.

    Sparaco M, Gaeta LM, Tozzi G et al (2006) Protein glutathionylation in human central nervous system: potential role in redox regulation of neuronal defense against free radicals. J Neurosci Res 83:256–263.

    CAS  Article  PubMed  Google Scholar 

  48. 48.

    Wilson C, Núñez MT, González-Billault C (2015) Contribution of NADPH oxidase to the establishment of hippocampal neuronal polarity in culture. J Cell Sci 128:2989–2995.

    CAS  Article  PubMed  Google Scholar 

  49. 49.

    Friedman J (2011) Oxidative stress and free radical damage in neurology. Oxidative Stress Free Radic Damage Neurol.

    Article  Google Scholar 

  50. 50.

    Glantz LA, Gilmore JH, Lieberman JA, Jarskog LF (2006) Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr Res 81:47–63.

    Article  PubMed  Google Scholar 

  51. 51.

    Kolomeets NS, Orlovskaya DD, Rachmanova VI, Uranova NA (2005) Ultrastructural alterations in hippocampal mossy fiber synapses in schizophrenia: a postmortem morphometric study. Synapse 57:47–55.

    CAS  Article  PubMed  Google Scholar 

  52. 52.

    Schmitt A, Hasan A, Gruber O, Falkai P (2011) Schizophrenia as a disorder of disconnectivity. Eur Arch Psychiatry Clin Neurosci 261:150–154.

    Article  PubMed Central  Google Scholar 

  53. 53.

    Stephan KE, Friston KJ, Frith CD (2009) Dysconnection in Schizophrenia: From abnormal synaptic plasticity to failures of self-monitoring. Schizophr Bull 35:509–527.

    Article  PubMed  PubMed Central  Google Scholar 

  54. 54.

    Manahan-Vaughan D, von Haebler D, Winter C et al (2008) A single application of MK801 causes symptoms of acute psychosis, deficits in spatial memory, and impairment of synaptic plasticity in rats. Hippocampus 18:125–134.

    CAS  Article  PubMed  Google Scholar 

  55. 55.

    Wiescholleck V, Manahan-Vaughan D (2013) Persistent deficits in hippocampal synaptic plasticity accompany losses of hippocampus-dependent memory in a rodent model of psychosis. Front Integr Neurosci 7:1–10.

    Article  Google Scholar 

  56. 56.

    O’Neill LAJ, Kaltschmidt C (1997) NF-κB: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci 20:252–258.

    Article  PubMed  Google Scholar 

  57. 57.

    Freudenthal R, Boccia MM, Acosta GB et al (2005) NF-κB transcription factor is required for inhibitory avoidance long-term memory in mice. Eur J Neurosci 21:2845–2852.

    Article  PubMed  Google Scholar 

  58. 58.

    Gutierrez H, Davies AM (2011) Regulation of neural process growth, elaboration and structural plasticity by NF-κB. Trends Neurosci 34:316–325.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  59. 59.

    Roussos P, Katsel P, Davis KL et al (2013) Convergent findings for abnormalities of the NF-κB signaling pathway in schizophrenia. Neuropsychopharmacology 38:533–539.

    CAS  Article  PubMed  Google Scholar 

  60. 60.

    Will CL, Lührmann R (2011) Spliceosome structure and function. Cold Spring Harb Perspect Biol 3:1–2.

    CAS  Article  Google Scholar 

  61. 61.

    Martins-de-Souza D, Gattaz WF, Schmitt A et al (2009) Proteome analysis of schizophrenia patients Wernicke’s area reveals an energy metabolism dysregulation. BMC Psychiatry 9:17.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  62. 62.

    Iwata K, Matsuzaki H, Manabe T, Mori N (2011) Altering the expression balance of hnRNP C1 and C2 changes the expression of myelination-related genes. Psychiatry Res 190:364–366.

    CAS  Article  PubMed  Google Scholar 

  63. 63.

    Saia-Cereda VM, Cassoli JS, Martins-de-Souza D, Nascimento JM (2017) Psychiatric disorders biochemical pathways unraveled by human brain proteomics. Eur Arch Psychiatry Clin Neurosci 267:3–17.

    Article  PubMed  Google Scholar 

  64. 64.

    English JA, Fan Y, Föcking M et al (2015) Reduced protein synthesis in schizophrenia patient-derived olfactory cells. Transl Psychiatry 5:e663.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  65. 65.

    Laursen LS, Chan CW, FfrenchConstant C (2011) Translation of myelin basic protein mRNA in oligodendrocytes is regulated by integrin activation and hnRNP-K. J Cell Biol 192:797–811.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  66. 66.

    Abdul-Rahman MF, Qiu A, Sim K (2011) Regionally specific white matter disruptions of fornix and cingulum in schizophrenia. PLoS ONE 6:1–11.

    CAS  Article  Google Scholar 

  67. 67.

    Ellison-Wright I, Bullmore E (2009) Meta-analysis of diffusion tensor imaging studies in schizophrenia. Schizophr Res 108:3–10.

    Article  PubMed  Google Scholar 

  68. 68.

    Fitzsimmons J, Hamoda HM, Swisher T et al (2014) Diffusion tensor imaging study of the fornix in first episode schizophrenia and in healthy controls. Schizophr Res 156:157–160.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  69. 69.

    Kunimatsu N, Aoki S, Kunimatsu A et al (2012) Tract-specific analysis of white matter integrity disruption in schizophrenia. Psychiatry Res Neuroimaging 201:136–143.

    Article  Google Scholar 

  70. 70.

    Rametti G, Junqué C, Falcón C et al (2009) A voxel-based diffusion tensor imaging study of temporal white matter in patients with schizophrenia. Psychiatry Res Neuroimaging 171:166–176.

    Article  Google Scholar 

  71. 71.

    Dracheva S, Davis KL, Chin B et al (2006) Myelin-associated mRNA and protein expression deficits in the anterior cingulate cortex and hippocampus in elderly schizophrenia patients. Neurobiol Dis 21:531–540.

    CAS  Article  PubMed  Google Scholar 

  72. 72.

    Cao M, Pu T, Wang L et al (2017) Early enriched physical environment reverses impairments of the hippocampus, but not medial prefrontal cortex, of socially-isolated mice. Brain Behav Immun 64:232–243.

    Article  PubMed  Google Scholar 

  73. 73.

    Makinodan M, Rosen KM, Ito S, Corfas G (2012) A critical period for social experience-dependent oligodendrocyte maturation and myelination. Science (80-) 337:1357–1360.

    CAS  Article  Google Scholar 

  74. 74.

    Pepper RE, Pitman KA, Cullen CL, Young KM (2018) How do cells of the oligodendrocyte lineage affect neuronal circuits to influence motor function, memory and mood? Front Cell Neurosci 12:1–14.

    CAS  Article  Google Scholar 

  75. 75.

    Biedler JL, Schachner M (1978) Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 38:3751–3757

    CAS  PubMed  Google Scholar 

  76. 76.

    McLaurin J, Trudel GC, Shaw IT et al (1995) A human glial hybrid cell line differentially expressing genes subserving oligodendrocyte and astrocyte phenotype. J Neurobiol 26:283–293.

    CAS  Article  PubMed  Google Scholar 

  77. 77.

    De Kleijn KMA, Zuure WA, Peijnenborg J et al (2019) Reappraisal of Human HOG and MO3.13 cell lines as a model to study oligodendrocyte functioning. Cells 8:1.

    CAS  Article  Google Scholar 

  78. 78.

    Kovalevich J, Langford D (2013) Considerations for the Use of SH-SY5Y Neuroblastoma Cells in Neurobiology. Neuronal cell culture: methods and protocols. Humana Press, Totowa, pp 9–21

    Chapter  Google Scholar 

Download references


The authors would like to thank all tissue donors and their families.


GSZ, GRO and DMS are supported by the São Paulo Research Foundation (FAPESP; grants 2018/14666-4, 2018/01410-1, 2017/25588-1, 2019/00098-7, 2018/01410-1) HIN is supported by CNPq and the São Paulo Research Foundation (FAPESP; grants 2017/50137-3, 2012/19278-6, and 2013/08216-2).

Author information




GSZ wrote the manuscript and made part of the data analysis, helped by GRO. DMS conceived and supervised the study and executed LC–MS/MS analyses. HIN headed data analysis, helped by BS. AS and PF provided brain tissue samples and followed the study development.

Corresponding authors

Correspondence to Helder I. Nakaya or Daniel Martins-de-Souza.

Ethics declarations

Conflict of interest

Authors have nothing to disclose.

Supplementary Information

Below is the link to the electronic supplementary material.


Supplementary Table 5 List of the pathways found altered in hippocampus samples (CA2/3), MK-801-treated oligodendrocytes (Oligodendrocytes) and MK-801-treated neurons (Neurons). X marks for the alteration in each condition, considering FDR < 0.05 (XLSX 12 KB)

Supplementary Table 1 Clinical data of schizophrenia patients and healthy controls (XLSX 12 KB)

Supplementary Table 2 Proteins differentially expressed in schizophrenia hippocampus (CA2/3) (DOCX 30 KB)

Supplementary Table 3 Proteins differentially expressed in MK-801-treated oligodendrocytes (DOCX 22 KB)

Supplementary Table 4 Proteins differentially expressed in MK-801-treated neurons (DOCX 18 KB)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zuccoli, G.S., Reis-de-Oliveira, G., Garbes, B. et al. Linking proteomic alterations in schizophrenia hippocampus to NMDAr hypofunction in human neurons and oligodendrocytes. Eur Arch Psychiatry Clin Neurosci (2021).

Download citation


  • Proteome
  • Hippocampus
  • Neurons
  • Oligodendrocytes
  • MK-801